Literature DB >> 24695293

Regulators adopt more orphan drugs.

Sara Reardon.   

Abstract

Mesh：

Year:  2014        PMID： 24695293     DOI： 10.1038/508016a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

Review 1.  FDA Policy and Cardiovascular Medicine.

Authors:  Joseph S Ross; Aaron S Kesselheim
Journal:  Circulation       Date:  2015-09-22       Impact factor: 29.690

2.  How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012.

Authors:  Derek J Ward; Angharad Slade; Tracey Genus; Orsolina I Martino; Andrew J Stevens
Journal:  BMJ Open       Date:  2014-10-24       Impact factor: 2.692

3.  Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.

Authors:  Aaron S Kesselheim; Carolyn L Treasure; Steven Joffe
Journal:  PLoS Med       Date:  2017-01-03       Impact factor: 11.069

4.  Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.

Authors:  Kerstin Noëlle Vokinger; Aaron S Kesselheim
Journal:  BMJ Open       Date:  2019-10-10       Impact factor: 2.692

5.  Capture and passive predation in times of COVID-19 pandemic.

Authors:  Samira Guennif
Journal:  Public Choice       Date:  2022-10-08

6.  Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Authors:  Olivier J Wouters; Panos G Kanavos; Martin McKEE
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.